Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis

PURPOSE: The availability of immune checkpoint inhibitors has deeply changed the therapeutic scenario of patients with advanced non-small cell lung cancer (NSCLC). Up until now, chemotherapy still represents the first-line treatment for patients with advanced NSCLC not harbouring genetic mutations o...

Descripción completa

Detalles Bibliográficos
Autores principales: Gebbia, Vittorio, Aiello, Marco Maria, Banna, Giuseppe, Blanco, Giusi, Blasi, Livio, Borsellino, Nicolò, Giuffrida, Dario, Mauro, Mario Lo, Mancuso, Gianfranco, Piazza, Dario, Savio, Giuseppina, Parra, Hector Soto, Valerio, Maria Rosaria, Verderame, Francesco, Vigneri, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2020
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581333/
https://www.ncbi.nlm.nih.gov/pubmed/33144881
http://dx.doi.org/10.3332/ecancer.2020.1113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581333/
https://www.ncbi.nlm.nih.gov/pubmed/33144881
http://dx.doi.org/10.3332/ecancer.2020.1113

Ejemplares similares